A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

Table 2 HK incidence

Time applied	Potassium level	Monthly probability				Source
		Patiromer		SoC
		Mean	SE	Mean	SE
Month 1	K + > 5 to ≤ 5.5	21.13%	3.32%	21.13%	3.32%	OPAL-HK CSR; distributed across threshold categories in line with published data [43, 46]
	K + > 5.5 to ≤ 6	1.66%	1.04%	1.66%	1.04%
	K + > 6	0.38%	0.50%	0.38%	0.50%
Month 2 & 3	K + > 5 to ≤ 5.5	14.00%	4.68%	15.00%	4.81%	OPAL-HK CSR [43]
	K + > 5.5 to ≤ 6	6.10%	3.23%	25.22%	5.86%
	K + > 6	1.40%	1.58%	5.78%	3.15%
Subsequent months^a	K + > 5 to ≤ 5.5	0.543%	0.054%	1.158%	0.116%	Horne et al. (2019); 'OPAL-HK CSR [43, 46]
	K + > 5.5 to ≤ 6	0.022%	0.002%	0.092%	0.009%
	K + > 6	0.005%	0.001%	0.021%	0.002%

HK Hyperkalaemia, RAASi Renin–angiotensin–aldosterone system inhibitor, SE Standard error, SoC Standard of care
^aSoC probabilities informed by HK recurrence rates observed in Horne et al. (2019) with recurrence events distributed in line with the distribution of initial HK events across potassium categories; patiromer estimates informed by Horne et al. (2019) after application of a HR based on OPAL-HK data from months 2 and 3; SE assumed as 10% of mean

ISSN: 1471-2369